CL2017001893A1 - Uso de prg4 como agente antiinflamatorio - Google Patents
Uso de prg4 como agente antiinflamatorioInfo
- Publication number
- CL2017001893A1 CL2017001893A1 CL2017001893A CL2017001893A CL2017001893A1 CL 2017001893 A1 CL2017001893 A1 CL 2017001893A1 CL 2017001893 A CL2017001893 A CL 2017001893A CL 2017001893 A CL2017001893 A CL 2017001893A CL 2017001893 A1 CL2017001893 A1 CL 2017001893A1
- Authority
- CL
- Chile
- Prior art keywords
- prg4
- inflammatory agent
- suffering
- proinflammatory
- inpellatory
- Prior art date
Links
- 229940121363 anti-inflammatory agent Drugs 0.000 title 1
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 2
- 102100032912 CD44 antigen Human genes 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 abstract 1
- 101001123332 Homo sapiens Proteoglycan 4 Proteins 0.000 abstract 1
- 102100028965 Proteoglycan 4 Human genes 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000005945 translocation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Psychiatry (AREA)
Abstract
<p>EN EL PRESENTE DOCUMENTO SE DIVULGAN MÉTODOS DE USO DE GLICOPROTEÍNA PRG4, TAMBIÉN CONOCIDA COMO LUBRICINA, PARA REDUCIR, INHIBIR O REGULAR A LA BAJA LAS VÍAS PROINFLAMATORIAS EN PACIENTES CON RIESGO DE SUFRIR O QUE SUFREN DE UNA RESPUESTA INFLAMATORIA O SÍNTOMA DE ALERGIA A TRAVÉS DE LA ANTAGONIZACIÓN DE CD44, LA REGULACIÓN DE LA PRODUCCIÓN DE CITOQUINAS PROINFLAMATORIAS, LA INHIBICIÓN DE LA TRANSLOCACIÓN DE NF-ΚΒ Y/O FACILITANDO LA ELIMINACIÓN DE ALÉRGENOS O RESTOS DE LA MATRIZ O RESTOS CELULARES INDUCTORES DE INFLAMACIÓN.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107799P | 2015-01-26 | 2015-01-26 | |
| US201562273059P | 2015-12-30 | 2015-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001893A1 true CL2017001893A1 (es) | 2018-06-15 |
Family
ID=55361962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001893A CL2017001893A1 (es) | 2015-01-26 | 2017-07-24 | Uso de prg4 como agente antiinflamatorio |
| CL2018003302A CL2018003302A1 (es) | 2015-01-26 | 2018-11-21 | Uso de prg4 como agente antiinflamatorio. (divisional solicitud 201701893). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003302A CL2018003302A1 (es) | 2015-01-26 | 2018-11-21 | Uso de prg4 como agente antiinflamatorio. (divisional solicitud 201701893). |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10967048B2 (es) |
| EP (2) | EP3718559B1 (es) |
| JP (2) | JP6758299B2 (es) |
| KR (1) | KR20170123619A (es) |
| CN (2) | CN107847556B (es) |
| AU (2) | AU2016211694B2 (es) |
| BR (1) | BR112017015310A8 (es) |
| CL (2) | CL2017001893A1 (es) |
| EA (1) | EA036291B1 (es) |
| ES (2) | ES2808199T3 (es) |
| IL (2) | IL253596B (es) |
| MA (1) | MA53108A (es) |
| MX (1) | MX2017009723A (es) |
| PH (1) | PH12017501323A1 (es) |
| RU (1) | RU2017129880A (es) |
| SG (2) | SG11201705636SA (es) |
| TN (1) | TN2017000270A1 (es) |
| WO (1) | WO2016123123A1 (es) |
| ZA (1) | ZA201705378B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9982027B2 (en) | 2013-10-22 | 2018-05-29 | Lubris Llc | Control of rheological properties of mixed hyaluronate/lubricin solutions |
| US10500250B2 (en) | 2013-11-26 | 2019-12-10 | Lubris Llc | Compositions and methods for inhibiting intercellular interactions |
| AU2016211694B2 (en) | 2015-01-26 | 2021-11-11 | Lubris Llc | Use of PRG4 as an anti-inflammatory agent |
| HK1251130A1 (zh) | 2015-05-01 | 2019-01-25 | Gentex Corporation | 头盔冲击衰减物品 |
| LT3300482T (lt) | 2015-05-19 | 2021-10-25 | Lubris Llc | Prg4 panaudojimas dinaminio regos aštrumo pagerinimui ir aukštesnės eilės aberacijų sumažinimui |
| CN106215170A (zh) * | 2016-08-23 | 2016-12-14 | 重庆医科大学 | 白细胞介素36α在制备治疗、诊断或预防脓毒症药物中的用途 |
| WO2018217921A1 (en) | 2017-05-23 | 2018-11-29 | Harmony Development Group, Inc. | Tethered implantable device having a vortical intracardiac velocity adjusting balloon |
| US10940002B2 (en) | 2017-06-28 | 2021-03-09 | Harmony Development Group, Inc. | Force transducting inflatable implant system including a dual force annular transduction implant |
| US11167122B2 (en) | 2018-03-05 | 2021-11-09 | Harmony Development Group, Inc. | Force transducting implant system for the mitigation of atrioventricular pressure gradient loss and the restoration of healthy ventricular geometry |
| CN108795867A (zh) * | 2018-06-05 | 2018-11-13 | 华东理工大学 | 用于构建结肠癌细胞腹膜转移体外三维模型的方法 |
| WO2019246522A1 (en) * | 2018-06-21 | 2019-12-26 | Lubris Llc | Lubricin for use in wound healing |
| CN109125709B (zh) * | 2018-08-23 | 2021-10-22 | 成都华创生物技术有限公司 | Trail突变体在制备治疗痤疮药物中的应用及一种制剂 |
| US12285182B2 (en) | 2018-10-10 | 2025-04-29 | Innova Vascular, Inc. | Devices and methods for removing an embolus |
| CN109620952A (zh) * | 2019-01-04 | 2019-04-16 | 北京中台恒基生物技术有限公司 | 一种肿瘤疫苗及其制备方法 |
| JP7667569B2 (ja) * | 2019-01-15 | 2025-04-23 | コーネル ユニバーシティー | 組換えラブリシン、並びにそれを使用するための組成物及び方法 |
| JP2022534724A (ja) * | 2019-06-03 | 2022-08-03 | ルブリス，エルエルシー． | がんを治療するためのｐｒｇ４の使用 |
| US20230256052A1 (en) * | 2020-07-07 | 2023-08-17 | University Of Connecticut | Method and composition for reducing or preventing bone resorption |
| IT202000022636A1 (it) * | 2020-09-25 | 2022-03-25 | Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter | “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma” |
| JP2022070061A (ja) * | 2020-10-26 | 2022-05-12 | サンスター株式会社 | 外用組成物 |
| CN114184792B (zh) * | 2021-11-17 | 2024-05-28 | 中国人民解放军总医院第二医学中心 | 冠心病标志物il-29及其应用 |
| KR102882547B1 (ko) * | 2022-05-16 | 2025-11-05 | 중앙대학교 산학협력단 | 인터루킨 1 베타 검출용 신규한 펩타이드 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6433142B1 (en) | 1989-08-08 | 2002-08-13 | Genetics Institute, Llc | Megakaryocyte stimulating factors |
| US6743774B1 (en) | 1999-04-23 | 2004-06-01 | Rhode Island Hospital | Tribonectins |
| US7001881B1 (en) | 1999-04-23 | 2006-02-21 | Rhode Island Hospital | Tribonectins |
| US6960562B2 (en) | 1999-04-23 | 2005-11-01 | Rhode Island Hospital, A Lifespan Partner | Tribonectin polypeptides and uses thereof |
| AU2001251342A1 (en) | 2000-04-05 | 2001-10-23 | Archer-Daniels-Midland Company | Ketogulonigenium endogenous plasmids |
| US7415381B2 (en) | 2003-01-09 | 2008-08-19 | Rhode Island Hospital, A Lifespan Partner | Joint friction sensing |
| US20060240037A1 (en) | 2003-06-04 | 2006-10-26 | Edward Fey | Methods and compositions for the treatment and prevention of degenerative joint disorders |
| WO2005016130A2 (en) * | 2003-08-14 | 2005-02-24 | Wyeth | Recombinant lubricin molecules and uses thereof |
| WO2005102363A2 (en) | 2004-04-20 | 2005-11-03 | Mucosal Therapeutics Llc | Methods of promoting cartilage healing or cartilage integration |
| US20080287369A1 (en) | 2004-07-23 | 2008-11-20 | Jay Gregory D | Compositions and Methods for Viscosupplementation |
| EP1827478A4 (en) | 2004-12-03 | 2009-08-05 | Mucosal Therapeutics Llc | METHODS OF TREATING JOINED OR SICK JOINTS |
| US20070111327A1 (en) | 2005-05-05 | 2007-05-17 | Jay Gregory D | Methods of detecting lubricin |
| CN101077887A (zh) * | 2006-05-23 | 2007-11-28 | 中国医学科学院血液学研究所 | 人促造血细胞增殖的细胞因子及其制备方法和用途 |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| WO2008143816A1 (en) | 2007-05-15 | 2008-11-27 | Mucosal Therapeutics | Compositions and methods for reducing friction between the surface of tendons or other soft tissues |
| US20090068247A1 (en) | 2007-09-12 | 2009-03-12 | Mucosal Therapeutics | Biocompatible devices coated with a tribonectin and methods for their production |
| US20090104148A1 (en) | 2007-09-18 | 2009-04-23 | Jay Gregory D | Treatment and prevention of joint disease |
| US20090191287A1 (en) | 2008-01-29 | 2009-07-30 | Johnson W Dudley | Mitigation of Inflammation-Related Injuries |
| US8506944B2 (en) | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
| HRP20150097T1 (hr) * | 2008-05-07 | 2015-03-27 | The Regents Of The University Of California | Terapijska nadopuna i poboljšanje vlaženja površine oka |
| ES2534082T3 (es) * | 2009-01-13 | 2015-04-17 | Lubris Llc | Modulación terapéutica de la lubricación del límite del epitelio vaginal |
| WO2010135736A2 (en) | 2009-05-22 | 2010-11-25 | Singularis Inc. | Application and uses of prg4 and therapeutic modulation thereof |
| CA2771110C (en) * | 2009-08-13 | 2019-02-26 | Singularis, Inc. | Prg4 treatment for interstitial cystitis |
| WO2011091000A2 (en) | 2010-01-19 | 2011-07-28 | Singularis, Inc. | Oral care compositions and methods |
| US20130116186A1 (en) | 2011-10-04 | 2013-05-09 | Rhode Island Hospital, A Lifespan Partner | Lubricin injections to maintain cartilage health |
| WO2014115022A1 (en) * | 2013-01-25 | 2014-07-31 | Baylor College Of Medicine | A helper-dependent adenoviral gene therapy delivery and expression system |
| US9982027B2 (en) | 2013-10-22 | 2018-05-29 | Lubris Llc | Control of rheological properties of mixed hyaluronate/lubricin solutions |
| US10500250B2 (en) | 2013-11-26 | 2019-12-10 | Lubris Llc | Compositions and methods for inhibiting intercellular interactions |
| AU2016211694B2 (en) | 2015-01-26 | 2021-11-11 | Lubris Llc | Use of PRG4 as an anti-inflammatory agent |
| US20180161393A1 (en) | 2015-01-26 | 2018-06-14 | Lubris Llc | Prg4 for treating gout and its symptoms |
| LT3300482T (lt) | 2015-05-19 | 2021-10-25 | Lubris Llc | Prg4 panaudojimas dinaminio regos aštrumo pagerinimui ir aukštesnės eilės aberacijų sumažinimui |
| US20170312335A1 (en) | 2015-12-30 | 2017-11-02 | Lubris Llc | Topical use of prg4 for treatment of allergy and symptoms of inflammation |
-
2016
- 2016-01-26 AU AU2016211694A patent/AU2016211694B2/en not_active Ceased
- 2016-01-26 JP JP2017535349A patent/JP6758299B2/ja active Active
- 2016-01-26 EP EP20170338.6A patent/EP3718559B1/en active Active
- 2016-01-26 BR BR112017015310A patent/BR112017015310A8/pt not_active IP Right Cessation
- 2016-01-26 MA MA053108A patent/MA53108A/fr unknown
- 2016-01-26 KR KR1020177023786A patent/KR20170123619A/ko not_active Ceased
- 2016-01-26 EP EP16704975.8A patent/EP3250221B1/en active Active
- 2016-01-26 CN CN201680007369.2A patent/CN107847556B/zh not_active Expired - Fee Related
- 2016-01-26 SG SG11201705636SA patent/SG11201705636SA/en unknown
- 2016-01-26 TN TN2017000270A patent/TN2017000270A1/en unknown
- 2016-01-26 ES ES16704975T patent/ES2808199T3/es active Active
- 2016-01-26 SG SG10201809947UA patent/SG10201809947UA/en unknown
- 2016-01-26 MX MX2017009723A patent/MX2017009723A/es unknown
- 2016-01-26 WO PCT/US2016/014952 patent/WO2016123123A1/en not_active Ceased
- 2016-01-26 US US15/546,192 patent/US10967048B2/en active Active
- 2016-01-26 ES ES20170338T patent/ES3014621T3/es active Active
- 2016-01-26 EA EA201791688A patent/EA036291B1/ru unknown
- 2016-01-26 CN CN202111044599.5A patent/CN113908257A/zh active Pending
- 2016-01-26 RU RU2017129880A patent/RU2017129880A/ru not_active Application Discontinuation
-
2017
- 2017-07-20 PH PH12017501323A patent/PH12017501323A1/en unknown
- 2017-07-20 IL IL253596A patent/IL253596B/en unknown
- 2017-07-24 CL CL2017001893A patent/CL2017001893A1/es unknown
- 2017-08-08 ZA ZA201705378A patent/ZA201705378B/en unknown
-
2018
- 2018-11-21 CL CL2018003302A patent/CL2018003302A1/es unknown
-
2020
- 2020-08-19 JP JP2020138846A patent/JP7212653B2/ja active Active
-
2021
- 2021-03-08 US US17/194,747 patent/US11717557B2/en active Active
- 2021-08-11 IL IL285553A patent/IL285553A/en unknown
-
2022
- 2022-02-08 AU AU2022200812A patent/AU2022200812A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003302A1 (es) | Uso de prg4 como agente antiinflamatorio. (divisional solicitud 201701893). | |
| CL2020000632A1 (es) | Composición y método para el tratamiento del autismo. | |
| CO2017011535A2 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
| CL2016002971A1 (es) | Combinación. | |
| EP4272834A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| CL2017003066A1 (es) | Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal | |
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| MX380252B (es) | Crenezumab para usarse en el tratamiento de enfermedad de alzheimer. | |
| MX389847B (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
| MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| MX2016014564A (es) | Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido. | |
| MX2019009783A (es) | Metodo para fabricar una barra que comprende antitranspirante. | |
| BR102014006335B8 (pt) | Método para produzir uma população isolada de células-tronco de polpa dentária imaturas (idpscs) e uso | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| CL2017000394A1 (es) | Composición que contiene cineol para la administración nasal | |
| MX2018007871A (es) | Composiciones para el cuidado personal. | |
| CL2017001615A1 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2. | |
| CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| CL2016002779A1 (es) | Composición para el cuidado de la piel | |
| CL2017001773A1 (es) | Análogos de calcitonina para tratar enfermedades y trastornos. | |
| CO2017002813A2 (es) | Derivados estabilizados de adrenomedulina y uso de los mismos |